{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:19:45Z","timestamp":1790713185623,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jvir.2021.03.535","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T01:42:43Z","timestamp":1617327763000},"page":"845-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry"],"prefix":"10.1016","volume":"32","author":[{"given":"Shelby","family":"Frantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirubahara","family":"Vaheesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Petroziello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Golzarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ripal","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Brower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun M.","family":"Rachakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2021.03.535_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2021.03.535_bib2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"Salem","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2021.03.535_bib3","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/j.gastro.2017.02.040","article-title":"Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality","volume":"152","author":"Serper","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2021.03.535_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOT.0000000000000726","article-title":"Changes in liver allocation in United States","volume":"25","author":"Leventhal","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.jvir.2021.03.535_bib5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/lt.25701","article-title":"Unfair advantages for hepatocellular carcinoma patients listed for liver transplant in short-wait regions following 2015 hepatocellular carcinoma policy change","volume":"26","author":"Brondfield","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jvir.2021.03.535_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.31318","article-title":"Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort","volume":"73","author":"Gabr","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2021.03.535_bib7","first-page":"593","article-title":"A\u00a0cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK","volume":"23","author":"Pollock","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jvir.2021.03.535_bib8","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1245\/s10434-017-5950-z","article-title":"The post-SIR-Spheres Surgery Study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy with yttrium-90 resin microspheres","volume":"24","author":"Pardo","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2021.03.535_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jvir.2018.03.018","article-title":"Radioembolization for hepatocellular carcinoma: a nationwide 10-year experience","volume":"29","author":"Tohme","year":"2018","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2021.03.535_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2021.03.535_bib11","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2021.03.535_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MOT.0000000000000727","article-title":"Striving for more just allocation of liver allografts between patients with and without hepatocellular carcinoma: successes and challenges","volume":"25","author":"Ahearn","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.jvir.2021.03.535_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2021.03.535_bib14","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jvir.2019.07.020","article-title":"Contemporary systematic review of health-related quality of life outcomes in locoregional therapies for\u00a0hepatocellular carcinoma","volume":"30","author":"Das","year":"2019","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2021.03.535_bib15","first-page":"2498","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Copur","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2021.03.535_bib16","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2021.03.535_bib17","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2021.03.535_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","author":"Levillain","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044321009398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044321009398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:07:38Z","timestamp":1760940458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044321009398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1051044321009398"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2021.03.535","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2021.03.535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2021","name":"copyright","label":"Copyright"}]}}